Clinical Trial Update: Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluate rivaroxaban for prevention of stroke in patients with non-valvular atrial fibrillation, showing efficacy and safety as an alterna…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED | Results posted: 2012-04-19